BRAIN: 18F-FLT PET Imaging of Meningoma: Predictive Indicators of Tumor Progress

Previous studies have shown that PET of 3'-deoxygen-3'-18F-fluorothoracic glycoside (18F-FLT) provides a non-invasive assessment of cell proliferation in meningococdenum.
the purpose of this prospective study is to assess the potential of 18F-FLT PET in predicting the progression of subsequent tumors of asymptomatic meningoma.
43 adult patients, 46 of whom were positive for MRI and 6 (6) were post-surgery residual meninges, and 60min dynamic 18F-FLTPET scans were performed before radiological monitoring.
calculated the maximum and average tumor blood ratio of tracer radioactivity (TBRmax, TBRmean).
tumor progress based on the newly released two-dimensional (2D) test endpoint criteria and the corresponding exploratory volume measurements of the Neuro-Tumor Response Assessment (RANO) Working Group.
using independent sample t-tests, Pearson-related coefficients, Cox regression, and receiver working characteristics (ROC) curve analysis.
18F-FLT PET image after the medium follow-up time (range 5-33.5 months).
the use of 2D-RANO (n s 11) relative to the volume standard (n s 10), the consistency of disease progress was found to be higher (91%).
2D-RANO standard, there was a significant increase in 18F-FLT intake in patients with developing diseases (TBRmax, 5.5±1.3 to 3.6±1.1, P .lt;0.0001; TBRmean, 3.5±0.8 to 2.4±0.7 P slt;0.0001).
ROC analysis shows that the optimal threshold for TBRmax is 4.4 (sensitivity 82%, specificity 77%, accuracy 78% and under-curve area (AUC) 0.871; TBRmean's P-lt;0.0001 and 2.8 (sensitivity 82%, specificity 77%, accuracy 78%, AUC 0.848; P s 0.001) are used to distinguish patients with disease progression from stable disease at an early stage.
the threshold remained the same and the diagnostic accuracy was similar after the exclusion of patients with residual meningomas or patients with stable disease and follow-up time of less than 12 months.
In addition, a positive correlation between absolute and relative tumor growth and 18F-FLT intake was found when excluding patients with absolute meningopathy or patients with stable conditions with short follow-up times (r -lt;0.513, P-lt;0.015).
used volumetric criteria to assess disease progress, the diagnostic accuracy was slightly less than 76%, while the threshold remained the same.
multivariable analysis showed that TBRmax was the only independent predictor of tumor progression (P .lt;0.046), while age, sex, baseline tumor size, tumor location, edema around the tumor, and residual meningoma had no effect.
study shows that 18F-FLT PET is a promising alternative to imaging biomarkers that can be used to predict the progression of subsequent tumors of un treated and asymptomatic residual meningomas.
origins: Asma Bashir, Mark B Vestergaard, Lisbeth Marner, PET imaging of meningioma with 18F-FLT: a predictor of tumour progression. MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here